title: Effects of balanced vasodilator, flosequinan, on aortic impedance in failing heart.
abstract: An arteriovenous vasodilator, flosequinan, has been shown to be effective for the treatment of acute heart failure. However, little is known as to its effect on aortic impedance, which is known to be a proper and precise expression of left ventricular (LV) afterload. To evaluate the acute cardiovascular effect of flosequinan in failing heart, we administered flosequinan intravenously to seven dogs with cardiac failure produced by an infusion of carbon powder (20-50 microm in diameter) into left main trunks of coronary artery. The LV-pump function was severely impaired after intracoronary injection of carbon powder, as evidenced by the findings that cardiac output, circumferential shortening velocity (mean Vcf), and peak +dP/dt of LV pressure were all decreased, associated with a significant increase in LV end-diastolic pressure. Flosequinan (0.9 mg/kg, i.v.) increased cardiac output by 28%, mean Vcf by 44%, and peak +dP/dt by 24%, whereas it decreased total systemic resistance by 32%, time constant of LV pressure decay by 22%, and LV end-diastolic pressure by 18%. Moreover, flosequinan substantially decreased the pulsatile components of LV afterload (i.e., characteristic impedance by 11% and arterial wave reflection coefficient by 45%). Thus flosequinan exerted not only positive inotropic but also positive lusitropic effects, in association with a significant reduction of both pulsatile and steady components of LV afterload, contributing to an improvement of LV-pump function in acute cardiac failure.
authors.affiliation: Second Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yano
authors.forename: M
authors.initials: M
authors.lastname: Kohno
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: T
authors.initials: T
authors.lastname: Hisaoka
authors.forename: T
authors.initials: T
authors.lastname: Tanigawa
authors.forename: K
authors.initials: K
authors.lastname: Ono
authors.forename: B
authors.initials: B
authors.lastname: Lee
authors.forename: M
authors.initials: M
authors.lastname: Konishi
authors.forename: M
authors.initials: M
authors.lastname: Matsuzaki
mesh_terms: D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000502:physiology; D009320:Atrial Natriuretic Factor / Q000097:blood; D004285:Dogs; D017097:Electric Impedance; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D009200:Myocardial Contraction / Q000187:drug effects; D011804:Quinolines / Q000494:pharmacology*; D013599:Systole / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology*; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D011804:Quinolines; D014665:Vasodilator Agents; C047316:flosequinan; D009320:Atrial Natriuretic Factor